Hypoxia-Inducible Factor-1 in Physiological and Pathophysiological Angiogenesis: Applications and Therapies.

Zimna A, Kurpisz M. · 2015

Read Hypoxia-Inducible Factor-1 in Physiological and Pathophysiological Angiogenesis: Applications and Therapies. by Zimna A, Kurpisz M. (2015) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc4471260.txt.

Introduction

Agnieszka Zimna and Maciej Kurpisz reviewed a low-oxygen response factor in blood vessel growth in BioMed Research International in 2015. Tissues starved of oxygen survive by switching on genes for new vessels, sugar use, and cell growth. The switch, a protein complex called HIF-1, senses oxygen directly and acts as the master regulator of this response.

New vessel growth, angiogenesis, can be healthy, as in wound healing and development, or harmful, as when tumors recruit their own supply. HIF-1 works alongside other vessel promoters, including VEGF, placental growth factor, and angiopoietins, in both settings. The review weighs HIF-1 as a treatment target from two directions: boosting it to rescue oxygen-starved tissue in ischemic disease, or blocking it to starve cancers. It also surveys delivery ideas, from genes to small molecules, tested toward those ends.

Catalog record

CREATORZimna A, Kurpisz M.
YEAR2015
COLLECTIONPAPERS
FORMATTXT
FILE SIZE69 KB
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC4471260

Browse the full library · About the Tower of Babel

Full text

The opening of the work, from the library's hosted text:

Hypoxia-Inducible Factor-1 in Physiological and Pathophysiological Angiogenesis: Applications and Therapies By Agnieszka Zimna, Maciej Kurpisz Published in: BioMed Research International DOI: 10.1155/2015/549412 ABSTRACT Abstract The cardiovascular system ensures the delivery of oxygen and nutrients to all cells, tissues, and organs. Under extended exposure to reduced oxygen levels, cells are able to survive through the transcriptional activation of a series of genes that participate in angiogenesis, glucose metabolism, and cell proliferation. The oxygen-sensitive transcriptional activator HIF-1 (hypoxia-inducible factor-1) is a key transcriptional mediator of the response to hypoxic conditions. The HIF-1 pathway was found to be a master regulator of angiogenesis. Whether the process is physiological or pathological, HIF-1 seems to participate in vasculature formation by synergistic correlations with other proangiogenic factors such as VEGF (vascular endothelial growth factor), PlGF (placental growth factor), or angiopoietins. Considering the important contributions of HIF-1 in angiogenesis and vasculogenesis, it should be considered a promising target for treating ischaemic diseases or cancer. In this review, we discuss the roles of HIF-1 in both physiological/pathophysiological angiogenesis and potential strategies for clinical therapy. 1. ANGIOGENESIS The circulatory system is the first biological system that is established during mammalian development [1]. Vessel formation occurs via only two basic mechanisms: vasculogenesis and angiogenesis [2]. During embryonic development, the primary vascular plexus is formed by vasculogenesis. This phenomenon involves de novo blood vessel formation from precursor cells called angioblasts (precursors of endothelial cells), whereas angiogenesis is the process by which blood vessels are formed from preexisting vessels. This process involves the remodelling of blood vessels into the large and small vessels that are typical for networks containing arteries, capillaries, and veins [3, 4]. Angiogenesis occurs in adult organisms and in embryos during development [3]. Angiogenesis consists of several basic steps. Briefly, biological signals such as hypoxia, ischaemia, and/or blood vessel damage upregulate the expression of proangiogenic growth factors that activate their receptors [5, 6]. Vascular permeability increases in response to VEGF, thereby allowing the extravasation of plasma proteins that form a primitive scaffold for migrating endothelial cells [7]. Angiopoietin-1 and angiopoietin-2 (Ang-1 and Ang-2) exert antagonistic functions during vessel development. Ang-1, which is a known natural inhibitor of vascular permeability, protects against plasma leakage, whereas Ang-2 is involved in vessel destabilisation via the detachment of smooth muscle cells and the promotion of permeabilisation [8, 9]. Subsequently, matrix metalloproteinases (MMPs) enhance angiogenesis through the degradation of matrix components [10]. Proliferating endothelial cells migrate to distant sites and then assemble as a solid cord that subsequently forms a lumen [11]. Integrins αβ promote endothelial cell adhesion and migration, whereas VE-cadherin increases cell survival and promotes endothelial cell adhesion [12–14]. Once the vessels are formed, pericytes and smooth muscle cells surround the newly created capillaries to stabilise the walls and to prevent leakage. Other factors such as Ang-1, PDGF-BB (platelet-derived growth factor BB), and PDGFR (platelet-derived growth factor receptor) participate in the maturation of blood vessels [8, 15]. Further expansion of the lumen diameter is called arteriogenesis [11]. Angiogenesis occurs in physiological states such as embryonic development, wound healing, or vessel penetration into avascular regions and in pathological states such as solid tumours formation, eye diseases, or chronic inflammatory disorders such as rheumatoid arthritis, psoriasis, and periodontitis [16, 17]. Pathophysiological angiogenesis exhibits differences in molecular pathways in comparison to physiological angiogenesis. Mutations in oncogenes and tumour suppressor genes and disruptions in growth factor activity play crucial roles during tumour angiogenesis [17]. The activation of the most prominent proangiogenic factor VEGF might be due to physiological stimuli such as hypoxia or inflammation or due to oncogene activation and tumour suppression function loss [18, 19]. Additionally, physiological angiogenesis such as that which occurs during embryonic development or wound healing seems to be dependent on VEGF signalling, whereas tumour angiogenesis adopts the ability to shift its dependence from VEGF to other proangiogenic pathways, for example, through the recruitment of myeloid cells and the upregulation of alternative vascular growth factors (PlGF and FGF, fibroblast growth factor) [17]. Moreover, tumour vessels are distinct from normal vasculature because they are disorganised and tortuous. Many morphological and functional differences exist between normal and tumour vasculature. For instance, tumour vessels are leakier than normal vessels, and endothelial cells growing within tumours carry genetic abnormalities [20, 21]. Elucidating the molecular mechanism of pathological angiogenesis might lead to the identification of potential therapeutic targets. Angiogenesis is a multistep process that requires the involvement of many biological signals and stimuli regardless of whether it is a physiological or pathological action. Proangiogenic factors are activated in response to some physical signals. Blood vessel damage, infarction, and blood flow reduction lead to decreases in O2 supply [11]. This state is called hypoxia, which is a potent angiogenic trigger that stimulates proangiogenic factor activity. 2. HYPOXIA 2.1. O2 Homeostasis Constant oxygen supply is essential for proper tissue function, development, and homeostasis. Thus, the vasculature network plays a crucial role in delivering oxygen particles (O2), nutrients, and other molecules within the entire human body [22]. Significantly, the first physiological system that becomes functional during mammalian embryonic development is the circulatory system. Governing O2 homeostasis in tissues by supplying an oxygen concentration adequate for the demand generated by the metabolic outputs of the tissue is essential. Oxygenic balance can be upset by rapid cellular division during embryonic development, by tumour growth, or by vasculature dysfunction due to vessel occlusion or rupture [23]. Notably, normal physiological O2 concentrations vary greatly from normal oxygen tension in the air depending on the type of tissue. For instance, arterial blood has a normal pO2 of 14%; myocardium, 10%; and skeletal muscle, 5%. In contrast, the natural pO2 levels of bone marrow, thymus, and cartilage are at or below 1% [24, 25]. The state when the O2 level decreases relative to physiological levels (characteristic for particular tissues) is called hypoxia [1]. 2.2. Hypoxia-Inducible Factor-1 Adaptation to low oxygen tension (hypoxia) in cells and tissues requires the activation of several genes that participate in angiogenesis, cell proliferation/survival, glucose and iron metabolism. In eukaryotic cells, hypoxia-inducible factor-1 (HIF-1) is a primary transcriptional mediator of the hypoxic response and master regulator of O2 homeostasis [26]. Hypoxia-inducible factor-1 was first discovered as a transcription factor that regulates erythropoietin (EPO) expression in response to low oxygen levels in the blood [27, 28]. HIF-1 consists of two different subunits, α and β (also known as aryl hydrocarbon nuclear receptor translocator (ARNT)); both subunits are members of the basic helix-loop-helix Per-Arnt-Sim (bHLH-PAS) transcription factor family [29, 30]. PAS and bHLH motifs are required for heterodimerisation between the HIF-1α and HIF-1β subunits [31]. Additionally, the bHLH domain of the HIF-1α/ARNT dimer is essential for DNA binding on hypoxia response elements (HREs) with the consensus sequence (G/ACGTG) in the promoters or enhancers of target genes [32]. Transcriptional activation and interactions with coactivators (such as CBP/p300) of HIF-1α are mediated by two domains, that is, C-TAD and N-TAD, which are on the C-terminus of the protein [33–35]. HIF-1β is a constitutively expressed subunit, whereas HIF-1α is translated continuously and degraded subsequently through ubiquitination under normoxic conditions [36, 37]. Thus far, three isoforms of HIF-α have been discovered (Figure 1(a)), that is, the previously discussed subunit HIF-1α and two other subunits, HIF-2α (also called endothelial

Read the complete text